Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 1
Submit an article Journal homepage
45
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Testing the ability of the nonalcoholic fatty liver disease fibrosis score to predict 1-year all-cause hospital admission

Trace HeavenerDepartment of Medicine, Division of Internal Medicine, Scott & White Medical Center–Temple, Temple, Texas; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1407-8736
, DO ORCID Icon,
Ahmed MemonCollege of Medicine, Texas A&M University, Temple, Texas;
, BA,
Shamyal KhanDepartment of Medicine, Division of Internal Medicine, Scott & White Medical Center–Temple, Temple, Texas;
, DO,
Sam DavisDepartment of Medicine, Division of Internal Medicine, Scott & White Medical Center–Temple, Temple, Texas; ORCID Iconhttp://orcid.org/0000-0002-1700-1048
, DO ORCID Icon,
Lauren SagerOffice of Biostatistics, Baylor Scott & White Research Institute–Temple, Temple, Texas;
, MS,
Sharon DeMorrowDepartment of Medical Physiology, College of Medicine, Texas A&M University, and Research Biologist, Central Texas Veterans Healthcare System, Temple, Texas;
, PhD &
Mark JeffriesDepartment of Medicine, Division of Gastroenterology, Scott & White Medical Center–Temple, Temple, Texas
, DO show all
Pages 26-29 | Received 03 Aug 2018, Accepted 29 Oct 2018, Published online: 29 Jan 2019

  • Angulo P, Hui JM, Marchesini G. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. doi: 10.1002/hep.21496.
  • Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3):e0173499. doi: 10.1371/journal.pone.0173499.
  • McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–1269. doi: 10.1136/gut.2010.216077.
  • Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57(4):1357–1365. doi: 10.1002/hep.26156.
  • Takahashi Y, Kurosaki M, Tamaki N, et al. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res. 2015;45(6):667–675. doi: 10.1111/hepr.12405.
  • Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10. doi: 10.1053/j.gastro.2015.04.043.
  • Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32(6):945–950. doi: 10.1111/j.1478-3231.2011.02753.x.
  • Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219–1229. doi: 10.3748/wjg.v19.i8.1219.
  • Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One 2014;9(2):e88569. doi: 10.1371/journal.pone.0088569.
  • Doycheva I, Cui J, Nguyen P, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43(1):83–95. doi: 10.1111/apt.13405.
  • Xun YH, Guo JC, Lou GQ, et al. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. Clin Exp Pharmacol Physiol. 2014;41(9):643–649. doi: 10.1111/1440-1681.12260.
  • Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS One. 2016;11(2):e0147237. doi: 10.1371/journal.pone.0147237.
  • Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol. 2015;110(9):1298–1304. doi: 10.1038/ajg.2015.241.
  • Ho CK, Maselli JH, Terrault NA, Gonzoles R. High rate of hospital admissions among patients with cirrhosis seeking care in US emergency departments. Dig Dis Sci. 2015;60(7):2183–2189. doi: 10.1007/s10620-015-3594-z.
  • Valbusa F, Bonapace S, Agnoletti D, et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One. 2017;12(3):e0173398. doi: 10.1371/journal.pone.0173398.
  • Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072. doi: 10.1056/NEJMra1503519.
  • Office of Financial Resources. Prevention and Public Health Fund. Atlanta, GA: CDC. https://www.cdc.gov/funding/pphf/index.html. Updated January 5, 2017. Accessed March 25, 2018.
  • Stremikis K, Connors C, Hoo E. Intensive Outpatient Care Program: A Care Model for the Medically Complex Piloted by Employers. New York, NY: The Commonwealth Fund; 2017. http://www.commonwealthfund.org/publications/case-studies/2017/sep/intensive-outpatient-care-program
  • Kripalani S, Theobald CN, Anctil B, Vasilevskis EE. Reducing hospital readmission: current strategies and future directions. Annu Rev Med. 2014;65(1):471–485. doi: 10.1146/annurev-med-022613-090415.
  • Feachem RG, Sekhri NK, White KL. Getting more for their dollar: a comparison of the NHS with California's Kaiser Permanente. BMJ. 2002;324(7330):135–141. doi: 10.1136/bmj.324.7330.135.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.